Dr. Reddy’s Laboratories Limited

Pharmaceuticals

Annual Returns

Cumulative Returns and Drawdowns



Fundamentals














Ownership




Margined





AI Summary

asof: 2026-09-14

Headwinds and Challenges

  • The rituximab biosimilar approval is for the U.S. market, but Dr. Reddy’s will not commercialize the product there itself. Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States. This means Dr. Reddy’s participation in the U.S. commercial opportunity is through a partner rather than directly.
  • The U.S. rituximab biosimilar market is described as one of the world’s most important pharmaceutical markets, but the announcement does not quantify the expected revenue or margin contribution to Dr. Reddy’s.
  • The company’s broader biosimilars business is still described as being in a build-out phase, with several pipeline products in oncology and autoimmune diseases at various stages of development for global launches, and with manufacturing capacity being ramped up to support global expansion plans. This indicates ongoing investment and execution requirements.
  • The forward-looking disclaimer in the press release identifies a wide range of risks and uncertainties that could cause actual results to differ materially from expectations, including general economic conditions, competition, regulatory changes, and the impact of acquisitions or reorganization.

Tailwinds and Growth Prospects

  • On August 1, 2026, Dr. Reddy’s announced that the U.S. FDA approved its rituximab biosimilar, a biosimilar to Rituxan® (rituximab), for the U.S. market. The approval strengthens the company’s growing global biosimilars portfolio and advances its biosimilars business in the United States.
  • The product was developed, manufactured and submitted for approval by Dr. Reddy’s. The approval followed a successful recent Pre-License Inspection (PLI) by the U.S. FDA at the company’s biologics manufacturing facility in Bachupally, Hyderabad. This reflects the company’s capabilities in bringing complex biologic medicines to highly regulated markets.
  • The rituximab biosimilar has already been commercialized in India, the European Union, the United Kingdom and more than 25 emerging markets, and has received marketing approval in Switzerland and Canada. This provides a track record of regulatory approvals and commercial presence across multiple geographies.
  • The company’s Biologics team has over 25 years of development into a fully integrated organization with capabilities in development, manufacture and commercialization of biosimilars in oncology and immunology. It has a current portfolio of six commercial products marketed in India, with some products marketed in more than 30 other countries.
  • In 2024, Dr. Reddy’s launched its first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This followed the launch of pegfilgrastim in the U.S. and Europe through a partner. The company also launched its rituximab biosimilar in Europe in 2025. The biosimilars business is described as having a key role in driving both near-term and long-term growth.
  • The company is ramping up manufacturing capacity to support global expansion plans, and has several pipeline products in oncology and autoimmune diseases in various stages of development for global launches across developed and emerging markets.

Key Risks

  • The press release includes a forward-looking statement disclaimer noting known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied. These include general economic conditions, performance of financial markets, credit defaults, currency exchange rates, interest rates, mortality and morbidity levels and trends, changing levels of competition, changes in laws and regulations and in the policies of central banks and/or governments, the impact of acquisitions or reorganization including related integration issues, and the susceptibility of the industry and markets to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (COVID-19).
  • Additional risks and uncertainties are identified in the company’s public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of the Annual Report on Form 20-F for the year ended March 31, 2026.
  • The company assumes no obligation to update any information contained in the press release.

Management Guidance Versus Observed Business Performance

  • The rituximab biosimilar approval was received on the FDA’s goal date, which Sridevi Khambhampaty, Global Head, Biologics, described as reflecting the company’s capabilities in developing and manufacturing complex biologic medicines for global markets. This indicates that the approval timeline met the regulatory goal date.
  • The product was developed, manufactured and submitted for approval by Dr. Reddy’s, and the approval followed a successful recent Pre-License Inspection (PLI) by the U.S. FDA at the Bachupally, Hyderabad biologics manufacturing facility. This suggests that the facility passed the inspection and that the company’s development and manufacturing capabilities performed as required for the approval.
  • The rituximab biosimilar has been commercialized in India, the European Union, the United Kingdom and more than 25 emerging markets, and has received marketing approval in Switzerland and Canada. This demonstrates execution of the company’s stated strategy of expanding its biosimilars portfolio across developed and emerging markets.
  • In 2024, the company launched its first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab), following the launch of pegfilgrastim in the U.S. and Europe through a partner. The company also launched its rituximab biosimilar in Europe in 2025. These launches are consistent with the company’s description of its biosimilars business as having a key role in driving near-term and long-term growth.
  • The company states it is ramping up manufacturing capacity to support global expansion plans and has several pipeline products in oncology and autoimmune diseases in various stages of development for global launches across developed and emerging markets. The observed performance of obtaining the U.S. FDA approval for rituximab biosimilar and the prior launches in multiple markets provide evidence of progress against this stated direction, though the announcement does not provide financial figures or specific guidance metrics to compare against.

Broker Narrative

The narrative shifted from a defensive Reduce in May 2023, focused on gRevlimid erosion, margin misses, India’s Covid base, Russia weakness, and pricing/regulatory risks, to an Accumulate by July 2026 that leaned on India and Russia/CIS growth, semaglutide relaunch, biosimilars, and high-margin US launches. Persistent themes were gRevlimid decay and margin pressure, which remained central as North America Generics declined 35.4% YoY and EBITDA missed estimates. Regulatory/facility concerns faded, while new risks around semaglutide supply disruption, European discounts, PSAI margin compression, and geopolitical costs emerged.

Fears that came true

  • gRevlimid sales erosion persisted: after the initial Q4FY23 decline, North America Generics revenue still fell 35.4% YoY to USD 233mn in Q1FY27 due to the gRevlimid high base, coinciding with later DISAPPOINTMENT calls such as the 2024-08-22 Buy with actual -14.4%.
  • Base business margin weakness recurred: the early EBITDA margin miss and EPS downgrades were followed by Q1FY27 reported EBITDA falling 61.3% YoY and adjusted EBITDA margin of ~13.3% missing estimates, around when Accumulate calls saw negative actual returns (2026-07-10 actual -5.3%).
  • Pricing pressure broadened: US price erosion flagged in 2023 was mirrored by Q1FY27 European distributor discounts and PSAI margin compression to 4.5%, weighing on overall profitability.

Optimism that failed

  • gRevlimid earnings support did not endure: the expectation of meaningful contribution through FY23-25E became a high-base drag by Q1FY27, with North America Generics revenue down 35.4% YoY.
  • China/EM expansion did not become the stated growth engine: the anticipated high double-digit growth in China/EM was absent from the last report’s tailwinds, which instead highlighted India and Russia/CIS growth.
  • European growth optimism faded: despite 35 product launches in Europe in FY23, EU sales declined YoY by Q1FY27 due to integration-related rebates and discounts.

Broker Timeline

63 broker calls · 2023-05-10 to 2026-07-23

   

Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.

🐞